Kidney stones and kidney function loss: a cohort study

R Todd Alexander, Brenda R Hemmelgarn, Natasha Wiebe, Aminu Bello, Catherine Morgan, Susan Samuel, Scott W Klarenbach, Gary C Curhan, Marcello Tonelli, Alberta Kidney Disease Network, R Todd Alexander, Brenda R Hemmelgarn, Natasha Wiebe, Aminu Bello, Catherine Morgan, Susan Samuel, Scott W Klarenbach, Gary C Curhan, Marcello Tonelli, Alberta Kidney Disease Network

Abstract

Objective: To investigate whether the presence of kidney stones increase the risk of end stage renal disease (ESRD) or other adverse renal outcomes.

Design: A registry cohort study using validated algorithms based on claims and facility utilisation data. Median follow-up of 11 years.

Setting: Alberta, Canada, between 1997 and 2009.

Participants: 3,089,194 adult patients without ESRD at baseline or a history of pyelonephritis. Of these, 1,954,836 had outpatient serum creatinine measurements and were included in analyses of chronic kidney disease and doubling of serum creatinine level.

Exposure: One or more kidney stones during follow-up.

Main outcome measures: Incident ESRD, development of stage 3b-5 chronic kidney disease (estimated glomerular filtration rate <45 mL/min/1.73 m(2)), and sustained doubling of serum creatinine concentration from baseline.

Results: 23,706 (0.8%) patients had at least one kidney stone, 5333 (0.2%) developed ESRD, 68,525 (4%) developed stage 3b-5 chronic kidney disease, and 6581 (0.3%) experienced sustained doubling of serum creatinine. Overall, one or more stone episodes during follow-up was associated with increased risk of ESRD (adjusted hazard ratio 2.16 (95% CI 1.79 to 2.62)), new stage 3b-5 chronic kidney disease (hazard ratio 1.74 (1.61 to 1.88)), and doubling of serum creatinine (hazard ratio 1.94 (1.56 to 2.43)), all compared with those without kidney stones during follow-up. The excess risk of adverse outcomes associated with at least one episode of stones seemed greater in women than in men, and in people aged <50 years than in those aged ≥ 50. However, the risks of all three adverse outcomes in those with at least one episode of stones were significantly higher than in those without stones in both sexes and age strata. The absolute increase in the rate of adverse renal outcomes associated with stones was small: the unadjusted rate of ESRD was 2.48 per million person days in people with one or more episodes of stones versus 0.52 per million person days in people without stones.

Conclusion: Even a single kidney stone episode during follow-up was associated with a significant increase in the likelihood of adverse renal outcomes including ESRD. However, the increases were small in absolute terms.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at ww.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790742/bin/aler005167.f1_default.jpg
Fig 1 Patient flow through study
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790742/bin/aler005167.f2_default.jpg
Fig 2 Forest plot of multivariable adjusted hazard ratios for kidney stones and ESRD. Absolute rates are ESRD rates per 1 000 000 person days

References

    1. Boddana P, Caskey F, Casula A, Ansell D. UK Renal Registry 11th annual report (December 2008). Chapter 14: UK Renal Registry and international comparisons. Nephron Clin Pract 2009;111(suppl 1):c269-76.
    1. USRDS United States Renal Data System. Incidence and prevalence of ESRD. Am J Kidney Dis 1997;30:S40-53.
    1. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23.
    1. Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ. The impact of cystinuria on renal function. J Urol 2002;168:27-30.
    1. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis 2004;44:799-805.
    1. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. International registry for primary hyperoxaluria. Am J Nephrol 2005;25:290-6.
    1. Edvardsson V, Palsson R, Olafsson I, Hjaltadottir G, Laxdal T. Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland. Am J Kidney Dis 2001;38:473-80.
    1. Ludwig M, Utsch B, Monnens LA. Recent advances in understanding the clinical and genetic heterogeneity of Dent’s disease. Nephrol Dial Transplant 2006;21:2708-17.
    1. Tosetto E, Ghiggeri GM, Emma F, Barbano G, Carrea A, Vezzoli G, et al. Phenotypic and genetic heterogeneity in Dent’s disease—the results of an Italian collaborative study. Nephrol Dial Transplant 2006;21:2452-63.
    1. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US Renal Data System 2009 annual data report. Am J Kidney Dis 2010;55:S1-420, A6-7.
    1. Stankus N, Hammes M, Gillen D, Worcester E. African American ESRD patients have a high pre-dialysis prevalence of kidney stones compared to NHANES III. Urol Res 2007;35:83-7.
    1. Rule AD, Bergstralh EJ, Melton LJ 3rd, Li X, Weaver AL, Lieske JC. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009;4:804-11.
    1. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 2011;6:2069-75.
    1. Hippisley-Cox J, Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney scores. BMC Fam Pract 2010;11:49.
    1. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol 2009;10:30.
    1. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 1985;11:267-9.
    1. Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol 1999;162:27-30.
    1. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, et al. Validation of a case definition to define hypertension using administrative data. Hypertension 2009;54:1423-8.
    1. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
    1. James MT, Hemmelgarn BR, Wiebe N, Pannu N, Manns BJ, Klarenbach SW, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 2010;376:2096-103.
    1. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. CMAJ 2008;179:1154-62.
    1. Coe FL, Evan AP, Worcester EM, Lingeman JE. Three pathways for human kidney stone formation. Urol Res 2010;38:147-60.
    1. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 2010;25:831-41.

Source: PubMed

3
Abonnieren